Education
About Us
Working with TipRanks
Follow Us
Alector Inc (ALEC)
NASDAQ:ALEC
ALEC Stock Chart & Stats
$2.21
-$0.09(-4.55%)
At close: 4:00 PM EST
$2.21
-$0.09(-4.55%)
Day’s Range― - ―
52-Week Range$0.87 - $3.40
Previous CloseN/A
Volume194.31K
Average Volume (3M)782.23K
Market Cap
$243.90M
Enterprise Value$200.74M
Total Cash (Recent Filing)$256.02M
Total Debt (Recent Filing)$36.23M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Apr 30, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding110,362,580
10 Day Avg. Volume724,948
30 Day Avg. Volume782,232
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.24
Price to Sales (P/S)7.63
P/FCF Ratio-0.87
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue9.54
Enterprise Value/Gross Profit10.69
Enterprise Value/Ebitda-1.51
Forecast
1Y Price Target
$2.10Price Target Upside-4.98% Downside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.84
Revenue Forecast (FY)$44.45M
Bulls Say, Bears Say
Bulls Say
Antibody Differentiation And UptakeLead anti‑amyloid antibody retains full effector function, which supports more efficient plaque clearance and provides a mechanistic differentiation versus competing antibodies.
Strategic Portfolio PivotShift toward a proprietary blood–brain barrier platform with focus on an anti‑amyloid antibody and a tau siRNA program may concentrate value and create a clearer development pathway.
Tau Modality Dosing AdvantageTau siRNA enables deeper target knockdown with peripheral dosing, avoiding intrathecal administration and easing potential broader adoption by patients and physicians.
Bears Say
Impact Of Prior Late‑stage FailureDiscontinuation of a late‑stage therapy after a trial failure undermines confidence in the near‑term pipeline and raises questions about execution and clinical risk.
Readout Uncertainty And Investor CautionAn interim futility analysis for the Alzheimer's trial represents a pivotal clinical readout that may prompt investor caution until efficacy and translatability are demonstrated.
Skepticism Around Progranulin BiologyRecent failures in progranulin‑targeting programs have lowered confidence in biological translatability and increase skepticism about similar approaches delivering functional benefits.
Alector News
ALEC FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was $0.87 and its highest was $3.40 in the past 12 months.
What is Alector Inc’s market cap?
Alector Inc’s market cap is $243.90M.
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is Apr 30, 2026 which is in 57 days.
How were Alector Inc’s earnings last quarter?
Alector Inc released its earnings results on Feb 25, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.374 by $0.034.
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Overvalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate is -0.27.
How many shares outstanding does Alector Inc have?
Alector Inc has 110,362,580 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Alector Inc reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.374. Following the earnings report the stock price went up 7.113%.
Which hedge fund is a major shareholder of Alector Inc?
Currently, no hedge funds are holding shares in ALEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alector Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.10 (-4.98% Downside)
$2.10 (-4.98% Downside)
Blogger Sentiment
Neutral
ALEC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 124.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.5%
Last 30 Days ▼ 12.8%
Last 30 Days ▼ 12.8%
News Sentiment
Bearish
Bullish news 25%
Bearish news 75%
Bearish news 75%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.75%
12-Months-Change
Fundamentals
Return on Equity
-181.56%
Trailing 12-Months
Asset Growth
-37.38%
Trailing 12-Months
Company Description
Alector Inc
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC Stock 12 Month Forecast
Average Price Target
$2.10
▼(-4.98% Downside)
Technical Analysis
Ownership Overview
Currently, No data available
---